Cargando…
Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras
AIM: The aim of this study was to analyze changes in the incidence, management and mortality of DFU in Sicilian Type 2 diabetic patients hospitalized between two eras, i.e. 2008–2013 and 2014–2019. METHODS: We compared the two eras, era1: 2008–13, era2: 2014–19. In era 1, n = 149, and in era 2, n =...
Autores principales: | Guarnotta, Valentina, Radellini, Stefano, Vigneri, Enrica, Cernigliaro, Achille, Pantò, Felicia, Scondotto, Salvatore, Almasio, Piero Luigi, Guercio, Giovanni, Giordano, Carla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651101/ https://www.ncbi.nlm.nih.gov/pubmed/34874944 http://dx.doi.org/10.1371/journal.pone.0259405 |
Ejemplares similares
-
Correction to: One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021) -
One Year of Dapaglifozin Add-On Therapy Ameliorates Surrogate Indexes of Insulin Resistance and Adiposity in Patients with Type 2 Diabetes Mellitus
por: Radellini, Stefano, et al.
Publicado: (2021) -
Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily
por: Silverii, G. Antonio, et al.
Publicado: (2021) -
Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2017) -
Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2018)